Abstract:Purpose/Objective(s)To compare the acute toxicity in two prospective, non-randomized trials of concurrent adjuvant chemoradiotherapy of capecitabine with or without oxaliplatin in patients with Stage II and III rectal cancer.Materials/MethodsTo further observe the tolerance and toxicity based on two fulfilled Phase I studies, two Phase II trials were launched, respectively, from March 2005 to November 2007. A total of 118 patients were treated with concurrent capecitabine and radiotherapy (Cap-CRT trial), with radiotherapy given to the pelvic area of DT 50 Gy/25F/5 weeks, and capecitabine at a dosage of 1,600 mg/m2, twice daily for 2 weeks followed by a 2nd cycle after a rest of 7 days. In another trial, oxaliplatin and capecitabine plus radiotherapy (Cap-Oxa-CRT trial, n = 90) was performed with a same schedule of radiotherapy and chemotherapy, while oxaliplatin at a dosage of 70 mg/m2 once a week, and capecitabine of 1,300 mg/m2/d, both for 2 cycles.ResultsGrade 1-4 leukopenia, diarrhea, and nausea were the most common toxic side effects among the patients in both trials, accounting for 70.2% (146/208), 65.9% (137/208), and 42.3% (88/208). However, some patients experienced Grade 3 or 4 side effects, including diarrhea (24.0%; 1%), leukopenia (4.3%; 0.0%), radiation-induced dermatitis (3.8%; 0.0%), cramping abdominal pain (1.0%; 0.0%), and fatigue (0.5%; 0.0%). When comparing the incidence of Grade 1-4 side effects between the two trials, patients in Cap-Oxa-CRT trial experienced significantly more nonhematological side effects, mainly in GI, including nausea (68.9% vs. 22.0%, p = 0.000), diarrhea (76.7% vs. 57.6%, p = 0.009), fatigue (47.8% vs. 23.7%, p = 0.000), hand-foot syndrome (14.4% vs. 4.2%, p = 0.029) and loss of appetite (57.8% vs. 30.5%, p = 0.000), but no significant difference between hematological side effects, i.e., leukopenia, anemia or thrombocytopenia. If further comparing the incidence of Grade 3 and 4 toxicity, the only significant difference was more Grade 3 and 4 diarrhea in Cap-oxa-CRT trial (33.3% vs. 18.6%, p = 0.009). Although the higher incidence of side effects in Cap-Oxa-CRT trial, no matter total Grade 1-4 or only Grade 3 and 4, there was no significant difference in a need to interrupt either radiotherapy (10.2% vs. 6.7%, p = 0.39) or chemotherapy (9.3% vs. 19.1%, p = 0.09) in Cap-CRT or Cap-oxa-CRT trial.ConclusionsIn patients with Stage II and III rectal adenocarcinoma treated with adjuvant chemoradiotherapy, both concurrent chemotherapy regimens are tolerable. No significant difference for treatment interruption or delay, though patients treated with oxaliplatin, capecitabine, and radiotherapy have suffered from more Grade 3 and 4 diarrhea. The long-term survival and local control of the two trials is being expected. Purpose/Objective(s)To compare the acute toxicity in two prospective, non-randomized trials of concurrent adjuvant chemoradiotherapy of capecitabine with or without oxaliplatin in patients with Stage II and III rectal cancer. To compare the acute toxicity in two prospective, non-randomized trials of concurrent adjuvant chemoradiotherapy of capecitabine with or without oxaliplatin in patients with Stage II and III rectal cancer. Materials/MethodsTo further observe the tolerance and toxicity based on two fulfilled Phase I studies, two Phase II trials were launched, respectively, from March 2005 to November 2007. A total of 118 patients were treated with concurrent capecitabine and radiotherapy (Cap-CRT trial), with radiotherapy given to the pelvic area of DT 50 Gy/25F/5 weeks, and capecitabine at a dosage of 1,600 mg/m2, twice daily for 2 weeks followed by a 2nd cycle after a rest of 7 days. In another trial, oxaliplatin and capecitabine plus radiotherapy (Cap-Oxa-CRT trial, n = 90) was performed with a same schedule of radiotherapy and chemotherapy, while oxaliplatin at a dosage of 70 mg/m2 once a week, and capecitabine of 1,300 mg/m2/d, both for 2 cycles. To further observe the tolerance and toxicity based on two fulfilled Phase I studies, two Phase II trials were launched, respectively, from March 2005 to November 2007. A total of 118 patients were treated with concurrent capecitabine and radiotherapy (Cap-CRT trial), with radiotherapy given to the pelvic area of DT 50 Gy/25F/5 weeks, and capecitabine at a dosage of 1,600 mg/m2, twice daily for 2 weeks followed by a 2nd cycle after a rest of 7 days. In another trial, oxaliplatin and capecitabine plus radiotherapy (Cap-Oxa-CRT trial, n = 90) was performed with a same schedule of radiotherapy and chemotherapy, while oxaliplatin at a dosage of 70 mg/m2 once a week, and capecitabine of 1,300 mg/m2/d, both for 2 cycles. ResultsGrade 1-4 leukopenia, diarrhea, and nausea were the most common toxic side effects among the patients in both trials, accounting for 70.2% (146/208), 65.9% (137/208), and 42.3% (88/208). However, some patients experienced Grade 3 or 4 side effects, including diarrhea (24.0%; 1%), leukopenia (4.3%; 0.0%), radiation-induced dermatitis (3.8%; 0.0%), cramping abdominal pain (1.0%; 0.0%), and fatigue (0.5%; 0.0%). When comparing the incidence of Grade 1-4 side effects between the two trials, patients in Cap-Oxa-CRT trial experienced significantly more nonhematological side effects, mainly in GI, including nausea (68.9% vs. 22.0%, p = 0.000), diarrhea (76.7% vs. 57.6%, p = 0.009), fatigue (47.8% vs. 23.7%, p = 0.000), hand-foot syndrome (14.4% vs. 4.2%, p = 0.029) and loss of appetite (57.8% vs. 30.5%, p = 0.000), but no significant difference between hematological side effects, i.e., leukopenia, anemia or thrombocytopenia. If further comparing the incidence of Grade 3 and 4 toxicity, the only significant difference was more Grade 3 and 4 diarrhea in Cap-oxa-CRT trial (33.3% vs. 18.6%, p = 0.009). Although the higher incidence of side effects in Cap-Oxa-CRT trial, no matter total Grade 1-4 or only Grade 3 and 4, there was no significant difference in a need to interrupt either radiotherapy (10.2% vs. 6.7%, p = 0.39) or chemotherapy (9.3% vs. 19.1%, p = 0.09) in Cap-CRT or Cap-oxa-CRT trial. Grade 1-4 leukopenia, diarrhea, and nausea were the most common toxic side effects among the patients in both trials, accounting for 70.2% (146/208), 65.9% (137/208), and 42.3% (88/208). However, some patients experienced Grade 3 or 4 side effects, including diarrhea (24.0%; 1%), leukopenia (4.3%; 0.0%), radiation-induced dermatitis (3.8%; 0.0%), cramping abdominal pain (1.0%; 0.0%), and fatigue (0.5%; 0.0%). When comparing the incidence of Grade 1-4 side effects between the two trials, patients in Cap-Oxa-CRT trial experienced significantly more nonhematological side effects, mainly in GI, including nausea (68.9% vs. 22.0%, p = 0.000), diarrhea (76.7% vs. 57.6%, p = 0.009), fatigue (47.8% vs. 23.7%, p = 0.000), hand-foot syndrome (14.4% vs. 4.2%, p = 0.029) and loss of appetite (57.8% vs. 30.5%, p = 0.000), but no significant difference between hematological side effects, i.e., leukopenia, anemia or thrombocytopenia. If further comparing the incidence of Grade 3 and 4 toxicity, the only significant difference was more Grade 3 and 4 diarrhea in Cap-oxa-CRT trial (33.3% vs. 18.6%, p = 0.009). Although the higher incidence of side effects in Cap-Oxa-CRT trial, no matter total Grade 1-4 or only Grade 3 and 4, there was no significant difference in a need to interrupt either radiotherapy (10.2% vs. 6.7%, p = 0.39) or chemotherapy (9.3% vs. 19.1%, p = 0.09) in Cap-CRT or Cap-oxa-CRT trial. ConclusionsIn patients with Stage II and III rectal adenocarcinoma treated with adjuvant chemoradiotherapy, both concurrent chemotherapy regimens are tolerable. No significant difference for treatment interruption or delay, though patients treated with oxaliplatin, capecitabine, and radiotherapy have suffered from more Grade 3 and 4 diarrhea. The long-term survival and local control of the two trials is being expected. In patients with Stage II and III rectal adenocarcinoma treated with adjuvant chemoradiotherapy, both concurrent chemotherapy regimens are tolerable. No significant difference for treatment interruption or delay, though patients treated with oxaliplatin, capecitabine, and radiotherapy have suffered from more Grade 3 and 4 diarrhea. The long-term survival and local control of the two trials is being expected.

Preliminary Evaluation of Concurrent Chemoradiotherapy of Capecitabine with or Without Oxaliplatin in Patients with Stage II and III Rectal Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Vs Capecitabine for Stage II to III Rectal Cancer

Long-term Results of Postoperative Chemoradiation Therapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase III Trial.

Toxicity Evaluation Of Capecitabine Concurrent Chemoradiotherapy For Stage Ii And Iii Rectal Cancer

Comparison of Concurrent Chemoradiotherapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone in Stage Ⅱ/Ⅲ Rectal Cancer Patients after Radical Operation

Interim Analysis of Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Versus Capecitabine Alone for Pathological Stage II and III Rectal Cancer: a Randomized Multicenter Phase III Trial

Postoperative Chemoradiotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine for Pathological Stage N2 Rectal Cancer.

A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

596P Comparison of Neoadjuvant Chemoradiotherapy with CAPEOX Versus Single-Agent Capecitabine in High-Risk Locally Advanced Rectal Cancer: Long-term Results from a Multicenter Randomized Controlled Trial (MONT-R)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer

Real-world assessment of capecitabine and oxaliplatin (CAPOX) tolerability in patients with localized colorectal cancer undergoing curative-intent therapy: A comprehensive single institution analysis.

Comparison of the Pathological Response and Adverse Effects of Oxaliplatin and Capecitabine versus Paclitaxel and Carboplatin in the Neoadjuvant Chemoradiotherapy Treatment Approach for Esophageal and Gastroesophageal Junction Cancer: A Randomized Control Trial Study

Comparison of Oxaliplatin with Cisplatin in Patients with Gastrointestinal Carcinoma

SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.

A Clinical Study to Evaluate the Toxicities of Adjuvant Chemoradiotherapy in Early Stage after Low-Anterior Resection for Locally Advanced Rectal Cancer

Oxaliplatin-based Adjuvant Chemotherapy Without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer.

Compliance and Safety of Neoadjuvant Intensity Modulated Radiotherapy (imrt) with Concurrent Capecitabine for Locally Advanced Rectal Cancer: Updated Results from A Phase Ii Trial (Chictr-Tnc-10001094).

Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials

Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer